Noppodor

NodThera is a clinical-stage biotechnology company focused on discovering and developing next-generation small molecule NLRP3 inflammasome inhibitors for the treatment of chronic inflammatory diseases. The company's lead candidates, such as NT-0796, are designed to penetrate the blood-brain barrier to treat neurodegenerative conditions like Parkinson's and Alzheimer's, as well as peripheral metabolic disorders including obesity and cardiovascular disease. By targeting the NLRP3 inflammasome, a key driver of the inflammatory response, NodThera aims to provide disease-modifying therapies for patients with high unmet medical needs. The company operates from locations in the UK and USA and is backed by prominent life science investors.